DrugId:  1
1. Name:  99mTc-glucarate
2. Groups:  Investigational
3. Description:  99mTc-glucarate(GLA) is an agent for non-invasive detection of breast tumours.
4. Indication:  Investigated for use/treatment in myocardial infarction.
DrugId:  2
1. Name:  Phosphoaminophosphonic Acid Guanylate Ester
2. Groups:  Experimental
3. Description:  A non-hydrolyzable analog of GTP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It binds tightly to G-protein in the presence of Mg2+. The nucleotide is a potent stimulator of adenylate cyclase. [PubChem]
4. Indication:  Not Available
DrugId:  3
1. Name:  Phosphoaminophosphonic Acid-Adenylate Ester
2. Groups:  Experimental
3. Description:  5'-Adenylic acid, monoanhydride with imidodiphosphoric acid. An analog of ATP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It is a potent competitive inhibitor of soluble and membrane-bound mitochondrial ATPase and also inhibits ATP-dependent reactions of oxidative phosphorylation. [PubChem]
4. Indication:  Not Available
DrugId:  4
1. Name:  Inclacumab
2. Groups:  Investigational
3. Description:  Inclacumab has been used in trials studying the treatment and prevention of Myocardial Infarction, Peripheral Arterial Disease (PAD), and Coronary Heart Disease, Graft Occlusion, Vascular.
4. Indication:  Not Available
DrugId:  5
1. Name:  Amediplase
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in myocardial infarction and thrombosis.
DrugId:  6
1. Name:  Rubidium chloride Rb-82
2. Groups:  Approved, Investigational
3. Description:  Rubidium chloride Rb-82 injection is a sterile nonpyrogenic solutions of rubidium Rb 82 chloride. It is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.
4. Indication:  Rubidium Rb 82 chloride injection is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.
DrugId:  7
1. Name:  Mesenchymal Stem Cells
2. Groups:  Investigational
3. Description:  Mesenchymal stem cells (MSCs) from healthy donors improve cardiac function in experimental acute myocardial infarction (AMI) models. Osiris' stem cells are derived from human bone marrow. The source marrow is voluntarily donated by healthy adults between the ages of 18 and 30 years. Blood samples from the donor are screened prior to donation for transmissible diseases, including HIV and hepatitis, and the medical and social history of each donor is obtained to ascertain whether signs, symptoms or behaviors consistent with high risk for carrying a disease are present.
4. Indication:  Investigated for use/treatment in heart disease and myocardial infarction.
DrugId:  8
1. Name:  Lanoteplase
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in myocardial infarction.
DrugId:  9
1. Name:  Cenderitide
2. Groups:  Investigational
3. Description:  Cenderitide is under investigation for the treatment of ST Elevation (STEMI) Myocardial Infarction of Anterior Wall.
4. Indication:  Not Available
DrugId:  10
1. Name:  Alferminogene Tadenovec
2. Groups:  Investigational
3. Description:  Alferminogene Tadenovec is Cardiumâ€™s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease. Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard cardiac infusion catheter.
4. Indication:  Investigated for use/treatment in angina, coronary artery disease, and heart disease.
DrugId:  11
1. Name:  INO-1001
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in brain cancer, cardiovascular disorders, and myocardial infarction.
DrugId:  12
1. Name:  Certoparin
2. Groups:  Approved, Investigational
3. Description:  Certoparin is a low molecular weight heparin, primarily active against factor Xa. Like other low molecular weight heparins, it is used to prevent deep venous thrombosis.
4. Indication:  Used in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.
DrugId:  13
1. Name:  Parnaparin
2. Groups:  Approved, Investigational
3. Description:  Parnaparin is an antithrombotic and belongs to the group of low molecular weight heparins.
4. Indication:  Used in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.
DrugId:  14
1. Name:  Nitrendipine
2. Groups:  Approved, Investigational
3. Description:  A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive. [PubChem]
4. Indication:  For the treatment of mild to moderate hypertension
DrugId:  15
1. Name:  Ammonia N-13
2. Groups:  Approved
3. Description:  Ammonia N 13 Injection, USP is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. The active ingredient, [13N] ammonia, has the molecular formula of 13NH3 with a molecular weight of 16.02.Ammonia N 13 Injection, USP is used for imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.
4. Indication:  For diagnostic Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.
DrugId:  16
1. Name:  Ridogrel
2. Groups:  Approved
3. Description:  Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction. However, there currently are no clinical indications for preferential use of ridogrel over aspirin.
4. Indication:  Used as an adjunctive therapy to induce thrombolysis in patients suffering acute myocardial infarction.
DrugId:  17
1. Name:  Anistreplase
2. Groups:  Approved
3. Description:  Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl group is chemically conjugated to a complex of bacterial-derived streptokinase and human Plasma-derived Lys-plasminogen proteins.
4. Indication:  For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
DrugId:  18
1. Name:  Lercanidipine
2. Groups:  Approved, Investigational
3. Description:  Lercanidipine is a calcium channel blocker of the dihydropyridine class.It is sold under various commercial names including Zanidip.
4. Indication:  For the treatment of Hypertension, management of angina pectoris and Raynaud's syndrome
DrugId:  19
1. Name:  Technetium Tc-99m pyrophosphate
2. Groups:  Approved
3. Description:  A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process. It has also been used in noninvasive tests for the distribution of organ involvement in different types of amyloidosis and for the evaluation of muscle necrosis in the extremities.
4. Indication:  For use as a skeletal imaging agent used to demonstrate areas of altered osteogenesis, and a cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction [FDA Label]. May also be used to image gated blood pools and detect gastrointetinal bleeding.
DrugId:  20
1. Name:  M40403
2. Groups:  Investigational
3. Description:  M40403 is a low molecular weight, synthetic manganese containing superoxide dismutase mimetic (SODm) that selectively removes superoxide anion.
4. Indication:  Intended for the treatment of pain and possibly various forms of cancer.
DrugId:  21
1. Name:  Streptokinase
2. Groups:  Approved, Investigational
3. Description:  Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci.
4. Indication:  For the treatment of acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or emolism and occlusion of arteriovenous cannulae
DrugId:  22
1. Name:  Reteplase
2. Groups:  Approved, Investigational
3. Description:  Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).
4. Indication:  For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
DrugId:  23
1. Name:  Clevidipine
2. Groups:  Approved, Investigational
3. Description:  Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option. 
4. Indication:  For the treatment of hypertension.
DrugId:  24
1. Name:  Nilvadipine
2. Groups:  Approved, Investigational
3. Description:  Nilvadipine is a calcium channel blocker (CCB) for treatment of hypertension.
4. Indication:  For the management of vasospastic angina, chronic stable angina and hypertension.
DrugId:  25
1. Name:  DG031
2. Groups:  Investigational
3. Description:  DG031, deCODE genetics's lead compound, is being developed for the prevention of myocardial infarction, or heart attack.
4. Indication:  Investigated for use/treatment in heart disease and myocardial infarction.
